Clinically differentiated therapies entering mature markets often face steep adoption resistance when high launch prices collide with aggressive payer restrictions. Overcoming this friction requires securing a strategic beachhead: a targeted focus area used to establish initial adoption and secure market traction, such as realigning pricing to alleviate payer resistance, or generating outcomes validation to justify economic value.  

This case study is part of Triangle Insights Group’s series, Levers for Launch: Navigating Early Market Resistance Across Brand Archetypes.  

The Commercial Dilemma 

Amgen launched Repatha (evolocumab) in 2015 as one of the first FDA-approved PCSK9 inhibitors for hypercholesterolemia and cardiovascular risk reduction. The biologic was positioned as a breakthrough option for patients with familial hypercholesterolemia or established atherosclerotic cardiovascular disease who remained uncontrolled on statins.

The asset fits the Late Challenger archetype, defined by high product differentiation within a mature market.

[h2] Despite clear unmet need, Repatha’s early adoption was constrained by three main factors: 

1. Stringent Payer Restrictions: Over 80% of commercial plans subjected Repatha to prior authorizations and step therapy, resulting in initial prescription rejection rates approaching 80%.
2. Premium Launch Pricing: An initial list price exceeding $14,000 per year collided with a cost-sensitive payer environment cautious of the budget impact across a sizeable eligible patient pool.
3. Evidence and Guideline Lag: Initial promotional messaging centered on surrogate LDL reductions, while cardiovascular outcomes trial readouts and formal clinical guideline endorsements lagged behind launch.  

Activating the Four Levers to Realign Value and Secure Growth

By aligning evidence, access, and advocacy, Amgen stabilized its trajectory and established Repatha as the market-leading PCSK9 inhibitor:

Positioning Strategy

Amgen repositioned Repatha around cardiovascular risk reduction for highest-risk patients using positive FOURIER results, framing the therapy around event prevention before establishing it as an integral part of guideline-driven secondary prevention alongside statins and ezetimibe.

Advocacy and Guideline Inclusion

Renowned cardiologists and patient groups such as the FH Foundation placed public pressure on payers regarding preventable cardiovascular events, helping secure a Class IIa recommendation from the ACC and AHA in 2018.

Evidence Generation 

Amgen demonstrated clinical efficacy through Phase III trials and the landmark 27,000-patient FOURIER trial showing a 20% reduction in major adverse cardiovascular events, supplemented by health economic modeling and the VESALIUS-CV primary prevention trial.

Market Access

 In October 2018, Amgen reduced Repatha’s U.S. list price by approximately 60% down to $5,900 per year, pioneered value-based outcomes contracts with refund guarantees, and expanded copay support so most commercial patients paid $0 to $5 out of pocket.

Key Strategic Considerations for Launch Teams

The commercial turnaround of Repatha highlights five considerations for commercial, medical, and market access leaders planning brand launches: 

1. Price with Purpose. If aiming for immediate traction, set launch pricing in a way that reflects payer-perceived value and budget impact. If a therapy’s price is not aligned with the value perceived by payers, access will be restricted, and adoption will stall in the short term. 

2. Transform the Narrative with Early Outcomes Data. Invest early in outcomes and health economics evidence to defend clinical value while proactively addressing cost-effectiveness challenges and payer skepticisms before they stall uptake. Clear, durable clinical outcomes will boost provider confidence and drive preferred access among competitive therapies.  
3. Advocacy to Drive Utilization and Access. Engage KOLs and patient groups not only to endorse the therapy but to publicly challenge restrictive payer practices preventing access; coordinated advocacy can both legitimize the product and pressure payers to ease access.
4. Send Clear Credibility Signals. Market confidence requires more than clinical trial evidence; it demands bold signals. Demonstrate commitment and instill confidence by taking direct action in communicating new evidence, pricing resets, and community engagement that show stakeholders the therapy is not only viable, but clinically imperative.
5. Defend and Deepen Market Share. Even after access improves, growth is not automatic. Actively reinforce long-term success by bolstering payer partnerships, investing in continued evidence generation, and defending share against new entrants to ensure sustained patient use as the market crowds. 

Read the summary of the entire 5-part series.